Injectable filling microsphere, injectable filling material containing injectable filling microsphere, and preparation and application of injectable filling material
Polylactic acid microspheres were prepared by membrane emulsification method of PLA-PEG-PLA block copolymer and surfactant, which solved the problems of poor hydrophilicity and uneven particle size distribution of polylactic acid microspheres, and achieved high yield and safety Good injectable filler microspheres meet the needs of medical beauty products.
Patent Information
- Application Number
- CN202411040877.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
The existing polylactic acid microspheres have poor hydrophilicity, which leads to sedimentation or aggregation, which increases the difficulty and safety risks of injection, and the uneven particle size distribution, resulting in poor safety and low bioavailability, and physical screening methods increase production steps and costs. .
Microspheres were prepared in membrane emulsification method by using PLA-PEG-PLA block copolymer and surfactant. Through membrane emulsification and curing processes, more than 90% of the microspheres had a particle size within the range of 20-50μm, and the production steps were simplified. Reduce the risk of infection.
Injectable filled microspheres with small particle size spans are achieved, which improves yield and use safety, avoids removal of phagocytosis cells, meets the needs of medical beauty products, and ensures ideal degradation time and bioavailability.
Smart Images

Figure CN118976148A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical aesthetics, and in particular to an injectable filling microsphere, an injectable filling material containing the microsphere, and preparation and application thereof. Background Art
[0002] Polylactic acid has good biocompatibility and is a biomedical material approved by the U.S. Food and Drug Administration (FDA). Polylactic acid will be slowly degraded into lactic acid in the body, and then completely degraded into carbon dioxide and water. Clinically proven, polylactic acid can stimulate the body to produce collagen, thereby improving the skin, correcting wrinkles, filling depressions and loose skin. Therefore, polylactic acid is widely used in the field of medical beauty. However, polylactic acid is a highly hydrophobic material with poor solubility and is very easy to precipitate, which not only makes injection more difficult, but also causes side effects such as subcutaneous nodules or redness and swelling due to uneven injection. It cannot adhere well to the facial tissue and is prone to aggregation and diffusion displacement.
[0003] At present, there are reports on the use of polyethylene glycol to modify polylactic acid and make microspheres to improve the hydrophilicity of polylactic acid. However, the particle size distribution of microspheres prepared by the existing method is uneven, and the particle size dispersion is wide, which will not only increase the probability of adverse reactions, but also cause needle blockage during use, resulting in the need for doctors to repeatedly handle the injection, increasing the risk of infection. The particle size is different, and the degradation speed of microspheres in the human body varies greatly, which will also aggravate the instability of the product. In addition, microspheres with too small particle size, for example, microspheres less than 20μm are easily cleaned up by phagocytes. After phagocytes engulf the microspheres, they are prone to form foreign body giant cells, causing adverse reactions such as chronic foreign body granulation, and the microspheres cannot induce collagen regeneration after being engulfed; microspheres with too large particle size will not only easily cause problems such as needle blockage and excessive pushing force during injection, but also have certain safety hazards due to their prolonged degradation time. Therefore, the industry often uses physical screening to obtain microspheres of suitable particle size so that the product particle size meets the use requirements, but physical screening will increase production steps, increase production costs and reduce product yields.
[0004] With the increasing demand for polylactic acid microsphere filling materials in the medical beauty industry, the medical beauty industry urgently needs to develop a method for preparing a biodegradable injectable filling material that is easy to disperse in water, has good safety, good particle size control, and high yield. Summary of the invention
[0005] The technical problem to be solved by the present application is to overcome the problem that the polylactic acid microspheres in the prior art have poor hydrophilicity, are easy to settle or aggregate in the preparation, and are easy to cause the problem of too little injection or over-injection, increase the difficulty of injection, and affect the safety of clinical use. And the polylactic acid microspheres modified by polyethylene glycol have uneven particle size distribution, wide particle size dispersion, and the resulting poor safety of use, low bioavailability, easy needle blockage during injection, and increased infection risk. Although microspheres of the target particle size can be obtained by physical screening, there are still defects such as low yield of microspheres in the effective particle size range, increased production steps, and increased production costs. The present application provides an injectable filled microsphere, an injectable filling material containing it, and its preparation and application. The injectable filled microspheres prepared by the method of the present application have a small particle size span, and even if no screening post-treatment is performed, it can ensure that more than 90% of the microspheres are distributed in a particle size of 20 to 50 μm. It can be seen that the yield of microspheres of the target particle size is high, the production steps are simplified, the production cost is reduced, the difficulty of injection is reduced, the risk of infection is reduced, and the safety of use is improved. At the same time, the particle size of the prepared microspheres meets the needs of medical beauty products, which can not only avoid being cleared by phagocytes, but also ensure an ideal degradation time in the body, with high safety and bioavailability.
[0006] This application solves the above technical problems through the following technical solutions.
[0007] The present application provides a method for preparing injectable filled microspheres, comprising the following steps: an organic phase comprising a PLA-PEG-PLA block copolymer and an organic solvent; an aqueous phase comprising a surfactant and water; the organic phase and the aqueous phase are mixed, emulsified by a membrane, and solidified to obtain the injectable filled microspheres;
[0008] The viscosity of the water phase is 4 to 25 mPa·s; and the pore size of the membrane tube during the membrane emulsification process is 35 to 65 μm.
[0009] In some embodiments, the organic solvent is selected from halogenated alkane solvents and / or ester solvents.
[0010] Wherein, the halogenated alkane solvent is a chlorinated alkane solvent, preferably selected from dichloromethane and
[0011] / or chloroform.
[0012] Wherein, the ester solvent is C2-C6 alkyl acetate, preferably ethyl acetate.
[0013] In some embodiments, the mass volume ratio of the PLA-PEG-PLA block copolymer to the organic solvent is 80-350 g / L, preferably 100-300 g / L, such as 200 g / L or 250 g / L.
[0014] In some embodiments, the viscosity of the aqueous phase is 5 to 23 mPa·s, for example 7.5 mPa·s, 9 mPa·s, 11 mPa·s, 13 mPa·s, 15 mPa·s, 17 mPa·s, 19 mPa·s, 21 mPa·s or 23 mPa·s.
[0015] In some embodiments, the surfactant is polyvinyl alcohol, preferably polyvinyl alcohol 1788.
[0016] In some embodiments, the water is purified water and / or water for injection.
[0017] In some embodiments, the mass volume ratio of the surfactant to the water is 8-45 g / L, preferably 10-40 g / L, for example 15 g / L, 20 g / L, 25 g / L, 30 g / L or 35 g / L.
[0018] In some embodiments, the method for preparing the aqueous phase comprises the following steps: mixing the surfactant and the water.
[0019] During the preparation of the aqueous phase, the mixing can be performed under stirring conditions as is conventional in the art, preferably mechanical stirring as is conventionally used in the art.
[0020] In some embodiments, the volume ratio of the organic phase to the aqueous phase is 1:(3-20), preferably 1:(5-15), for example 1:10.
[0021] In some embodiments, the membrane emulsification is rapid membrane emulsification. Preferably, the rapid membrane emulsification comprises the following steps: passing the mixed material of the organic phase and the aqueous phase through a membrane tube.
[0022] In some embodiments, during the membrane emulsification process, the pore size of the membrane tube is 40-60 μm, such as 45 μm, 50 μm or 55 μm.
[0023] In some embodiments, during the membrane emulsification process, the membrane is passed through 1 to 3 times, preferably 1 to 2 times.
[0024] In some embodiments, during the membrane emulsification process, the membrane flow rate is 0.4 to 1.8 L / min, for example, 1 L / min.
[0025] In some embodiments, the curing method includes a reduced pressure volatilization method and / or an air flow blowing method. According to the conventional art, the purpose of the curing is to remove the organic solvent in the system and promote the curing of the emulsion into microspheres.
[0026] Wherein, when the curing is performed by a reduced pressure volatilization method, the curing can be performed by a vacuum pump according to the conventional method in the art.
[0027] Wherein, when the curing is carried out by the reduced pressure volatilization method, the vacuum degree of the curing is 0.02-0.1 MPa.
[0028] Wherein, when the curing is carried out by the air flow blowing method, the flowing gas is selected from at least one of compressed air, nitrogen and inert gas.
[0029] In some embodiments, the solidification operation may be followed by at least one of washing, collecting and drying according to conventional procedures in the art.
[0030] The washing liquid used in the washing is water and / or an alcohol solvent, preferably at least one of purified water, water for injection and anhydrous ethanol.
[0031] Wherein, the collection method includes filtration and / or centrifugation.
[0032] Wherein, the drying method is selected from at least one of low-temperature freeze drying, vacuum reduced pressure drying and forced air drying.
[0033] Wherein, the drying time is 4 to 40 hours.
[0034] In some embodiments, the number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000-130,000, wherein the number average molecular weight of PEG is 100-800.
[0035] The number average molecular weight of the PLA-PEG-PLA block copolymer is preferably 40,000 to 120,000, more preferably 40,000 to 90,000, such as 50,000, 60,000, 70,000 or 80,000.
[0036] The number average molecular weight of PEG is preferably 200-800, more preferably 400-800, for example 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750 or 800.
[0037] Wherein, the PLA in the PLA-PEG-PLA block copolymer is selected from at least one of L-polylactic acid, D-polylactic acid and racemic polylactic acid, preferably L-polylactic acid.
[0038] Wherein, the melting point of the PLA-PEG-PLA block copolymer is 140-200°C, preferably 140-180°C.
[0039] The preparation method of the PLA-PEG-PLA block copolymer comprises the following steps: in an inert atmosphere and under the action of a catalyst, polyethylene glycol and lactide undergo a polymerization reaction to obtain the PLA-PEG-PLA block copolymer; wherein the number average molecular weight of the polyethylene glycol is 100 to 800, and the mass ratio of the polyethylene glycol to the lactide is (1 to 20):1000.
[0040] During the preparation of the PLA-PEG-PLA block copolymer, the number average molecular weight of the polyethylene glycol is 200-800, preferably 400-800, for example 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750 or 800.
[0041] During the preparation of the PLA-PEG-PLA block copolymer, the mass ratio of the polyethylene glycol to the lactide is (3-20):1000, preferably (3-10):1000.
[0042] During the preparation of the PLA-PEG-PLA block copolymer, the lactide is selected from L-lactide and / or D-lactide.
[0043] During the preparation of the PLA-PEG-PLA block copolymer, the inert atmosphere is selected from nitrogen and / or an inert gas. Preferably, the inert gas is selected from helium and / or argon.
[0044] In the preparation process of the PLA-PEG-PLA block copolymer, the catalyst is selected from a tin catalyst and / or a zinc catalyst. Preferably, the tin catalyst is selected from at least one of dibutyltin diacetate, dibutyltin dibenzoate, tri-n-butyl methoxytin, dibutyltin dilaurate, stannous octoate, stannous octoate and stannous isooctanoate. Preferably, the zinc catalyst is selected from zinc lactate and / or zinc acetate.
[0045] During the preparation of the PLA-PEG-PLA block copolymer, the molar ratio of the catalyst to the lactide is (10 -5 ~10 -3 ): 1, preferably (10 -4 ~10 -3 ): 1, for example 4.6×10 -4 :1.
[0046] In the preparation process of the PLA-PEG-PLA block copolymer, the polymerization reaction is melt polymerization. Preferably, the melt polymerization specifically comprises the following steps: under the protection of an inert atmosphere, adding the polyethylene glycol and the catalyst to the molten lactide to carry out a polymerization reaction.
[0047] During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction temperature is 110-180°C, preferably 125-165°C, such as 135°C.
[0048] During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction time can be a conventional time for such reactions in the art, preferably 4 to 24 hours.
[0049] In the preparation process of the PLA-PEG-PLA block copolymer, the polymerization reaction may be followed by at least one of recrystallization, collecting precipitates, washing and drying.
[0050] The present application also provides an injectable filled microsphere, which is prepared by the method for preparing the injectable filled microsphere as described above.
[0051] In some embodiments, the content of the injectable filling microspheres having a particle size of 20 to 50 μm is not less than 90%.
[0052] The present application also provides an injectable filling material, which includes the injectable filling microspheres as described above.
[0053] In some embodiments, the mass percentage of the injectable filling microspheres to the injectable filling material is 5% to 40%.
[0054] In some embodiments, the injectable filling material further includes at least one of a hyaluronic acid-like substance, a cross-linked hyaluronic acid, a buffer and an anesthetic.
[0055] Wherein, the hyaluronic acid substance is selected from hyaluronic acid and / or hyaluronate. The hyaluronic acid substance can be a non-cross-linked hyaluronic acid substance conventionally considered by those skilled in the art.
[0056] Preferably, the hyaluronate is selected from at least one of sodium hyaluronate, potassium hyaluronate, calcium hyaluronate and zinc hyaluronate.
[0057] Wherein, the molecular weight of the hyaluronic acid substance is 10WDa to 300WDa.
[0058] Wherein, the mass percentage of the hyaluronic acid substance in the injectable filling material is 0% to 0.3%.
[0059] Wherein, the mass percentage of the cross-linked hyaluronic acid in the injectable filling material is 0% to 2%.
[0060] The buffer may be a buffer acceptable in the field of medical aesthetics and medicine, preferably a phosphate buffer.
[0061] Wherein, the anesthetic is selected from at least one of lidocaine hydrochloride, lidocaine carbonate, tetracaine, prilocaine, procaine, mepivacaine and bupivacaine, preferably lidocaine hydrochloride.
[0062] The mass percentage of the anesthetic to the injectable filling material is 0.2% to 0.4%, preferably 0.3%.
[0063] The present application also provides a method for preparing the injectable filling material as described above, which specifically comprises the following steps: mixing the components in the injectable filling material.
[0064] In some embodiments, the mixing conditions and methods may be conventional in the art, and generally the system may be mixed uniformly.
[0065] In some embodiments, the mixing operation may further include a degassing operation.
[0066] The degassing method may be a negative pressure degassing method commonly used in the art.
[0067] The present application also provides a use of the injectable filling microspheres as described above or the injectable filling materials as described above as raw materials in the preparation of medical or cosmetic products.
[0068] Among them, the medical or cosmetic products include filling and shaping products.
[0069] On the basis of conforming to the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present application.
[0070] The reagents and raw materials used in this application are commercially available.
[0071] The positive progress of this application is that this application adopts a specific membrane emulsification method to prepare injectable filling microspheres with a small particle size span. Even without post-screening treatment, it can ensure that more than 90% of the microspheres are distributed in a particle size range of 20 to 50 μm. It can be seen that the yield of microspheres with a target particle size is high, which simplifies the production steps, reduces production costs, reduces the difficulty of injection, reduces the risk of infection, and improves safety of use. At the same time, the particle size of the prepared microspheres meets the needs of medical beauty products, which can avoid being cleared by phagocytes and ensure an ideal degradation time in the body, and has high safety of use and bioavailability. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 This is a scanning electron microscope image of the injectable filled microspheres prepared in Example 1. DETAILED DESCRIPTION
[0073] The present application is further described below by way of examples, but the present application is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the product instructions.
[0074] The viscosity in this application is the viscosity measured at 25°C using a rotational viscometer.
[0075] The reagents and raw materials used in the following examples are all commercially available, and the purity of the reagents used is injection grade.
[0076] In the following examples and comparative examples, water is water for injection.
[0077] The membrane emulsifier used in the following examples and comparative examples is a high-throughput SPG membrane emulsifier model KH-125 produced by Jiasheng (Hong Kong) Technology Co., Ltd.
[0078] Preparation of PLA-PEG-PLA block copolymers 1 to 6:
[0079] ① Weigh 1 kg of L-lactide and add it to the reactor, pass nitrogen protection, and adjust the temperature of the reactor to 110-130°C until the L-lactide is completely melted;
[0080] ② After L-lactide is completely melted, polyethylene glycol (see Table 1 for the amount added) and 1.3 g of stannous isooctanoate are injected into the reaction bottle, nitrogen is passed through to maintain a positive pressure in the system, the temperature is raised to 135°C, and the reaction is kept at this temperature for 24 hours; after recrystallization and drying, PLA-PEG-PLA block copolymer is obtained.
[0081] During the preparation of PLA-PEG-PLA block copolymers 1 to 6, the selected polyethylene glycol number average molecular weight, and the mass ratio of polyethylene glycol to L-lactide are shown in Table 1 below.
[0082] Table 1
[0083]
[0084]
[0085] Example 1 Preparation of injectable filled microspheres
[0086] ① Preparation of aqueous phase: Add an appropriate amount of purified water to the container, slowly add 30g of polyvinyl alcohol 1788, stir until completely dissolved, and adjust the volume to 1L to obtain an aqueous phase with a viscosity of 12mPa·s;
[0087] ② Preparation of organic phase: Add an appropriate amount of dichloromethane to a container, weigh 20 g of the PLA-PEG-PLA block copolymer 1 prepared above, add it to the container, stir to completely dissolve it and adjust the volume to 100 mL to obtain an organic phase;
[0088] ③ Membrane emulsification: slowly pour the above organic phase into the aqueous phase, use a membrane emulsifier to emulsify the mixed liquid, the membrane tube pore size is 50μm, the number of membrane passes is 1, and the emulsion is obtained;
[0089] ④ Solidification: Stir the emulsified emulsion and blow nitrogen to volatilize the dichloromethane until the dichloromethane is completely evaporated;
[0090] ⑤ Collection: After the dichloromethane is completely evaporated, the suspension is centrifuged to collect the solid components, which are then dried to obtain injectable filled microspheres.
[0091] Examples 2 to 4 and Comparative Examples 1 to 4
[0092] Compared with Example 1, the only difference is the type and concentration of PLA-PEG-PLA block copolymer, the concentration of surfactant in the aqueous phase, the viscosity of the aqueous phase, the membrane tube pore size or the number of membrane passes. Other condition parameters are the same as Example 1. Please refer to Table 2 for details.
[0093] Table 2
[0094]
[0095]
[0096] Comparative Example 5
[0097] ① Preparation of aqueous phase: Add 30 g of polyvinyl alcohol 1788 into an appropriate amount of purified water, stir until completely dissolved, and adjust the volume to 1 L to obtain an aqueous phase with a viscosity of 12 mPa·s;
[0098] ② Preparation of organic phase: Add 20 g of the PLA-PEG-PLA block copolymer 1 prepared above into an appropriate amount of dichloromethane, stir to completely dissolve it and adjust the volume to 100 mL to obtain an organic phase;
[0099] ③ Emulsification: slowly pour the above organic phase into the aqueous phase, mechanically stir and emulsify to obtain an emulsion;
[0100] ④ Solidification: Stir the emulsified emulsion to completely evaporate the dichloromethane in the system;
[0101] ⑤ Collection: After the dichloromethane is completely evaporated, the suspension is centrifuged to collect the solid components, which are then dried to obtain injectable filled microspheres.
[0102] Effect Example 1
[0103] (1) The number average molecular weight of the PLA-PEG-PLA block copolymers 1 to 6 was tested. The results are shown in Table 3.
[0104] (2) The PLA-PEG-PLA block copolymers 1 to 6 were respectively made into injectable filled microspheres as test samples using the preparation process of the comparative example 5, and the changes in the pH value and lactic acid content of the system before and after sterilization of the test samples were tested.
[0105] pH value test method before and after sterilization: Take 1g of the sample prepared above, add it to an injection bottle, add 4mL of phosphate buffer with a pH value of 7.0 (pH value of the system before sterilization) to the bottle, mix well and sterilize with high-pressure steam, test the pH value of the system after sterilization, and compare the changes in pH value of the system before and after sterilization. The results are shown in Table 3.
[0106] Table 3
[0107]
[0108]
[0109] Test method for lactic acid content in the system before and after sterilization: Take 1 g of the sample prepared above, add it to an injection bottle, add 4 mL of phosphate buffer with a pH value of 7.0 to the bottle, mix well and then sterilize with high-pressure steam, test the lactic acid content in the system before and after sterilization, and calculate the change in lactic acid content. The results are shown in Table 4.
[0110] Table 4
[0111] Raw materials to be tested Changes in lactic acid content in the system before and after sterilization PLA-PEG-PLA block copolymer 1 0.057mg / mL PLA-PEG-PLA block copolymer 2 0.085mg / mL PLA-PEG-PLA block copolymer 3 0.029mg / mL PLA-PEG-PLA block copolymer 5 0.049mg / mL PLA-PEG-PLA block copolymer 6 0.270mg / mL
[0112] The results showed that the PLA-PEG-PLA block copolymer prepared above had ideal thermal stability, and the pH value of the system and the lactic acid content in the system changed little before and after sterilization.
[0113] Effect Example 2
[0114] The dispersibility of the injectable filled microspheres in water, the morphology of the injectable filled microspheres, the proportion of microspheres with a particle size of 20 to 50 μm and the particle size span of the injectable filled microspheres obtained in the above examples and comparative examples were observed. The results are shown in Table 5.
[0115] Test method for dispersion performance in water: disperse 0.3 g of injectable filled microspheres in 5 g of water, vortex mix for 5 minutes and then let stand to observe the dispersion of the injectable filled microspheres in the system. The results are shown in Table 5.
[0116] The morphology of the injectable filled microspheres prepared in the above examples and comparative examples was observed using a scanning electron microscope. The results are shown in Table 5. Among them, the scanning electron microscope image of the injectable filled microspheres prepared in Example 1 is shown in Table 5. Figure 1 .
[0117] The particle size distribution of the injectable filled microspheres prepared in the above embodiments and comparative examples was tested using a laser particle size analyzer, and the proportion of microspheres with a particle size of 20 to 50 μm and the particle size span were calculated. The results are shown in Table 5.
[0118]
[0119] Table 5
[0120]
[0121] The results show that the viscosity of the aqueous phase and the pore size of the membrane tube during membrane emulsification have a great influence on the particle size and particle size span of the injectable filled microspheres.
[0122] According to the results of Comparative Example 1, when the viscosity of the water phase is low, the emulsion is easy to merge and demulsify during the preparation of the microspheres, resulting in the adhesion and agglomeration of some of the collected polymer microspheres, poor balling performance, low yield of microspheres of the target particle size, and high production cost.
[0123] According to the results of Comparative Examples 1, 4 and 5, when the aqueous phase viscosity is low, the membrane tube pore size is large or the microspheres prepared by mechanical stirring have a large particle size span, needle blockage is likely to occur during injection, increasing the risk of infection, and the degradation rate in the human body varies greatly, increasing the probability of adverse reactions after injection and increasing the instability of the product effect. The content of microspheres with a particle size range of 20 to 50 μm is low, the yield is low, and the production cost is high.
[0124] According to the results of Comparative Examples 2 and 3, when the water phase viscosity is large or the membrane tube pore size is small, although the particle size span is small, the overall particle size is small, and the content of microspheres with a particle size range of 20 to 50 μm is low. Low yield and production cost High, and easily phagocytosed by phagocytes, causing adverse reactions such as chronic foreign body granulation The phagocytosed microspheres cannot induce collagen regeneration and have low bioavailability.
[0125] Finally, it should be noted that in this application, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements that are not explicitly listed, or also includes elements that are inherent to such process, method, article or apparatus.
[0126] Although the present application has been disclosed above through the description of the specific embodiments of the present application, it should be understood that those skilled in the art can design various modifications, improvements or equivalents to the present application within the spirit and scope of the attached scheme. These modifications, improvements or equivalents should also be considered to be included in the scope of protection claimed in the present application.
Claims
1. A method for preparing injectable filled microspheres, It is characterized in that The method comprises the following steps: the organic phase comprises a PLA-PEG-PLA block copolymer and an organic solvent; the aqueous phase comprises a surfactant and water; the organic phase and the aqueous phase are mixed, emulsified by a membrane, and solidified to obtain the injectable filled microspheres; The viscosity of the water phase is 4 to 25 mPa·s; and the pore size of the membrane tube during the membrane emulsification process is 35 to 65 μm.
2. The method for preparing the injectable filled microspheres according to claim 1, It is characterized in that The method for preparing the injectable filled microspheres satisfies at least one of the following conditions (1) to (13): (1) The organic solvent is selected from halogenated alkane solvents and / or ester solvents; (2) the mass volume ratio of the PLA-PEG-PLA block copolymer to the organic solvent is 80 to 350 g / L; (3) The viscosity of the aqueous phase is 5 to 23 mPa·s; (4) The surfactant is polyvinyl alcohol; (5) The water is purified water and / or water for injection; (6) The mass volume ratio of the surfactant to the water is 8 to 45 g / L; (7) The method for preparing the aqueous phase comprises the following steps: mixing the surfactant and the water; (8) The volume ratio of the organic phase to the aqueous phase is 1:(3-20); (9) The membrane emulsification is rapid membrane emulsification; (10) During the membrane emulsification process, the pore size of the membrane tube is 40 to 60 μm; (11) During the membrane emulsification process, the number of membrane passes is 1 to 3 times; (12) The curing method includes a reduced pressure volatilization method and / or an air flow blowing method; (13) The solidification step further includes at least one of washing, collecting and drying.
3. The method for preparing the injectable filled microspheres according to claim 2, It is characterized in that The method for preparing the injectable filled microspheres satisfies at least one of the following conditions (1) to (13): (1) The halogenated alkane solvent is a chlorinated alkane solvent, preferably selected from dichloromethane and / or chloroform; (2) The ester solvent is acetic acid C 2 ~C 6 Alkyl ester, preferably ethyl acetate; (3) the mass volume ratio of the PLA-PEG-PLA block copolymer to the organic solvent is 100 to 300 g / L; (4) The surfactant is polyvinyl alcohol 1788; (5) The mass volume ratio of the surfactant to the water is 10 to 40 g / L; (6) The volume ratio of the organic phase to the aqueous phase is 1:(5-15); (7) During the membrane emulsification process, the number of membrane passes is 1 to 2 times; (8) When the curing is carried out by a reduced pressure volatilization method, the vacuum degree of the curing is 0.02 to 0.1 MPa; (9) When the curing is performed by the air flow blowing method, the flowing gas is selected from at least one of compressed air, nitrogen and an inert gas; (10) The washing liquid used in the washing is water and / or an alcohol solvent, preferably at least one of purified water, water for injection and anhydrous ethanol; (11) The collection method includes filtration and / or centrifugation; (12) The drying method is selected from at least one of low-temperature freeze drying, vacuum drying and forced air drying; (13) The drying time is 4 to 40 hours.
4. A method for preparing injectable filled microspheres according to any one of claims 1 to 3, It is characterized in that The number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000-130,000, wherein the number average molecular weight of PEG is 100-800.
5. The method for preparing the injectable filled microspheres according to claim 4, It is characterized in that The method for preparing the injectable filled microspheres satisfies at least one of the following conditions (1) to (5): (1) The number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000 to 120,000; (2) The number average molecular weight of the PEG is 200 to 800; (3) PLA in the PLA-PEG-PLA block copolymer is selected from at least one of L-polylactic acid, D-polylactic acid and racemic polylactic acid; (4) the melting point of the PLA-PEG-PLA block copolymer is 140-200° C.; (5) The preparation method of the PLA-PEG-PLA block copolymer comprises the following steps: in an inert atmosphere and under the action of a catalyst, polyethylene glycol and lactide undergo a polymerization reaction to obtain the PLA-PEG-PLA block copolymer; wherein the number average molecular weight of the polyethylene glycol is 100 to 800, and the mass ratio of the polyethylene glycol to the lactide is (1 to 20):1000.
6. The method for preparing the injectable filled microspheres according to claim 5, It is characterized in that The method for preparing the injectable filled microspheres satisfies at least one of the following conditions (1) to (13): (1) The number average molecular weight of the PLA-PEG-PLA block copolymer is 40,000 to 90,000; (2) The number average molecular weight of the PEG is 400 to 800; (3) the melting point of the PLA-PEG-PLA block copolymer is 140-180° C.; (4) During the preparation of the PLA-PEG-PLA block copolymer, the number average molecular weight of the polyethylene glycol is 200 to 800, preferably 400 to 800; (5) During the preparation of the PLA-PEG-PLA block copolymer, the mass ratio of the polyethylene glycol to the lactide is (3-20):1000, preferably (3-10):1000; (6) During the preparation of the PLA-PEG-PLA block copolymer, the lactide is selected from L-lactide and / or D-lactide; (7) During the preparation of the PLA-PEG-PLA block copolymer, the inert atmosphere is selected from nitrogen and / or an inert gas; preferably, the inert gas is selected from helium and / or argon; (8) In the preparation process of the PLA-PEG-PLA block copolymer, the catalyst is selected from a tin catalyst and / or a zinc catalyst; preferably, the tin catalyst is selected from at least one of dibutyltin diacetate, dibutyltin dibenzoate, tri-n-butyl methoxytin, dibutyltin dilaurate, stannous octoate, stannous octoate and stannous isooctanoate; preferably, the zinc catalyst is selected from zinc lactate and / or zinc acetate; (9) During the preparation of the PLA-PEG-PLA block copolymer, the molar ratio of the catalyst to the lactide is (10 -5 ~10 -3 ): 1, preferably (10 -4 ~10 -3 ):1; (10) During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction is melt polymerization; preferably, the melt polymerization specifically comprises the following steps: adding the polyethylene glycol and the catalyst to the molten lactide under the protection of an inert atmosphere to carry out a polymerization reaction; (11) During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction temperature is 110 to 180° C., preferably 125 to 165° C.; (12) During the preparation of the PLA-PEG-PLA block copolymer, the polymerization reaction time is 4 to 24 hours; (13) In the preparation process of the PLA-PEG-PLA block copolymer, the polymerization reaction further comprises at least one of recrystallization, collecting precipitate, washing and drying.
7. An injectable filling microsphere, It is characterized in that Prepared by the method for preparing injectable filled microspheres as claimed in any one of claims 1 to 6; Preferably, the content of the injectable filling microspheres having a particle size of 20 to 50 μm is not less than 90%.
8. An injectable filling material, It is characterized in that comprising the injectable filled microspheres as claimed in claim 7; Preferably, the mass percentage of the injectable filling microspheres to the injectable filling material is 5% to 40%; Preferably, the injectable filling material further comprises at least one of hyaluronic acid, cross-linked hyaluronic acid, buffer and anesthetic; More preferably, the hyaluronic acid substance is selected from hyaluronic acid and / or hyaluronate; further preferably, the hyaluronate is selected from at least one of sodium hyaluronate, potassium hyaluronate, calcium hyaluronate and zinc hyaluronate; More preferably, the molecular weight of the hyaluronic acid substance is 10WDa to 300WDa; More preferably, the mass percentage of the hyaluronic acid substance in the injectable filling material is 0% to 0.3%; More preferably, the mass percentage of the cross-linked hyaluronic acid in the injectable filling material is 0% to 2%; More preferably, the buffer is a phosphate buffer; More preferably, the anesthetic is selected from at least one of lidocaine hydrochloride, lidocaine carbonate, tetracaine, prilocaine, procaine, mepivacaine and bupivacaine, and further preferably lidocaine hydrochloride; More preferably, the mass percentage of the anesthetic to the injectable filling material is 0.2% to 0.4%, and even more preferably 0.3%.
9. A method for preparing the injectable filling material according to claim 8, It is characterized in that The method comprises the following steps: mixing the components of the injectable filling material; Preferably, the mixing operation also includes a degassing operation.
10. Use of the injectable filling microspheres as claimed in claim 7 or the injectable filling material as claimed in claim 8 as a raw material in the preparation of medical or cosmetic products; Preferably, the medical or cosmetic products include filling and shaping products.
Citation Information
Cited By
Continuous preparation method and application of screening-free narrow-distribution polyester microspheres
CN122381376A
